Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Mucosis B.V.
DescriptionMucosal-based influenza vaccine using Mimopath technology containing trivalent split influenza antigen and bacterium-like particles (BLPs) as self-adjuvanting vehicles
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase I/II
Standard IndicationInfluenza virus
Indication DetailsPrevent influenza infection
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today